Avalo Therapeutics Stock Current Valuation
| AVTX Stock | USD 10.13 0.48 4.97% |
Valuation analysis of Avalo Therapeutics helps investors to measure Avalo Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Avalo Therapeutics' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 0.16 in 2024, despite the fact that Enterprise Value is likely to grow to (4.1 M). Fundamental drivers impacting Avalo Therapeutics' valuation include:
Price Book 5.0293 | Enterprise Value 24.7 M | Enterprise Value Ebitda (0.19) | Price Sales 129.2638 | Trailing PE 0.1073 |
Overvalued
Today
Please note that Avalo Therapeutics' price fluctuation is risky at this time. Calculation of the real value of Avalo Therapeutics is based on 3 months time horizon. Increasing Avalo Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Avalo Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Avalo Stock. However, Avalo Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.13 | Real 4.77 | Target 0.75 | Hype 10.24 | Naive 8.35 |
The intrinsic value of Avalo Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Avalo Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Avalo Therapeutics helps investors to forecast how Avalo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Avalo Therapeutics more accurately as focusing exclusively on Avalo Therapeutics' fundamentals will not take into account other important factors: Avalo Therapeutics Company Current Valuation Analysis
Avalo Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Avalo Therapeutics Current Valuation | 24.69 M |
Most of Avalo Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Avalo Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Avalo Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Avalo Therapeutics is extremely important. It helps to project a fair market value of Avalo Stock properly, considering its historical fundamentals such as Current Valuation. Since Avalo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Avalo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Avalo Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Avalo Therapeutics has a Current Valuation of 24.69 M. This is 99.83% lower than that of the Biotechnology sector and 99.47% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.85% higher than that of the company.
Avalo Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Avalo Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Avalo Therapeutics could also be used in its relative valuation, which is a method of valuing Avalo Therapeutics by comparing valuation metrics of similar companies.Avalo Therapeutics is currently under evaluation in current valuation category among its peers.
Avalo Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Avalo Therapeutics from analyzing Avalo Therapeutics' financial statements. These drivers represent accounts that assess Avalo Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Avalo Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 112.3M | 308.1M | 194.0M | 47.4M | 2.5M | 2.4M | |
| Enterprise Value | 117.0M | 305.8M | 175.5M | 53.7M | (4.4M) | (4.1M) |
Avalo Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Avalo Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Avalo Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Avalo Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.31 | ||||
| Operating Margin | (51.65) % | ||||
| Current Valuation | 24.69 M | ||||
| Shares Outstanding | 10.46 M | ||||
| Shares Owned By Insiders | 5.86 % | ||||
| Shares Owned By Institutions | 65.20 % | ||||
| Number Of Shares Shorted | 10.06 K | ||||
| Price To Book | 5.03 X | ||||
| Price To Sales | 129.26 X | ||||
| Revenue | 1.92 M | ||||
| Gross Profit | (7.94 M) | ||||
| EBITDA | (27.95 M) | ||||
| Net Income | (31.54 M) | ||||
| Cash And Equivalents | 11.25 M | ||||
| Cash Per Share | 1.20 X | ||||
| Total Debt | 537 K | ||||
| Debt To Equity | 5.62 % | ||||
| Current Ratio | 0.98 X | ||||
| Book Value Per Share | 2.18 X | ||||
| Cash Flow From Operations | (30.68 M) | ||||
| Short Ratio | 0.33 X | ||||
| Earnings Per Share | 94.42 X | ||||
| Target Price | 35.0 | ||||
| Number Of Employees | 19 | ||||
| Beta | 1.03 | ||||
| Market Capitalization | 106 M | ||||
| Total Asset | 20.99 M | ||||
| Retained Earnings | (335.13 M) | ||||
| Working Capital | 3.78 M | ||||
| Net Asset | 20.99 M |
About Avalo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Avalo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avalo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avalo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Avalo Stock Analysis
When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.